Echinocandin activity against Aspergillus spp. and the importance of pharmacodynamics

References

• Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diag Microbiol Infect Dis 1998; 30: 251–255
   PubMed Web of Science ®Google Scholar
• Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27: 369–388
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006; 43: 215–222
   PubMed Web of Science ®Google Scholar
• Meyer V, Damveld RA, Arentshorst M, et al. Survival in the presence of antifungals: genome-wide expression profiling of Aspergillus niger in response to sublethal concentrations of caspofungin and fenpropimorph. J Biol Chem 2007; 282: 32935–32948
   PubMed Web of Science ®Google Scholar
• Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001–3012
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandin MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Micro 1998; 36: 2950–2956
   PubMed Web of Science ®Google Scholar
• Paderu P, Garcia-Effron G, Balashov S, et al. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007; 51: 2253–2256
   PubMed Web of Science ®Google Scholar
• Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480–1489
   PubMed Web of Science ®Google Scholar
• Merck & Co. Cancidas (caspofungin) package insert. Whitehouse Station, NJ; 2008.
   Google Scholar
• Astellas Pharma US. Mycamine (micafungin) package insert. Deerfield, IL; 2005.
   Google Scholar
• Pfizer Inc. Eraxis (anidulafungin) package insert. New York, NY; 2006.
   Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142–1151
   PubMed Web of Science ®Google Scholar
• Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001; 45: 2845–2855
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42: 2898–2905
   PubMed Web of Science ®Google Scholar
• Warn PA, Morrissey G, Morrissey J, Denning DW. Activity of micafungin (FK463) against an intraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003; 51: 913–919
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464–1471
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857–1869
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12–23
   PubMed Web of Science ®Google Scholar
• van Vianen W, de Marie S, ten Kate MT, et al. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006; 57: 732–740
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Lowther J, et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1187–1192
   PubMed Web of Science ®Google Scholar
• Andes D, Diekema DJ, Pfaller MA, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008; 52: 539–550
   PubMed Web of Science ®Google Scholar
• Louie A, Deziel M, Liu W, et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058–5068
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571
   PubMed Web of Science ®Google Scholar
• Kartsonis NA, Saah AJ, Lipka CJ, Taylor AF, Sable CA. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005; 50: 196–205
   PubMed Web of Science ®Google Scholar
• Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337–349
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2–12
   PubMed Web of Science ®Google Scholar
• Buell, D, Kovanda, L, Drake, T, Frisco, C. Alternative day dosing of micafungin for esophageal candidiasis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 16–19, December, 2005. American Society for Microbiology 2005: Abstract M-719.
   Google Scholar
• Safdar A, Rodriguez G, Rolston KVI, et al. High dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 157–164
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888–2897
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high–loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289–1297
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 2008; 46: 327–360
   PubMed Web of Science ®Google Scholar